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Increased cyclic AMP-phosphodiesterase activity in 
peripheral blood leukocytes is associated with the 
immune and inflammatory hyperreactivity that char-
acterizes atopic dertnatitis. Atopic phosphodiesterase 
has high sensitivity to a variety of enzyme inhibitors, 
suggesting an increased therapeutic advantage. The 
objective of this study was to use ill Vitl'O assays to 
identify a potent phosphodiesterase inhibitor and 
then to investigate its effectiveness in treating atopic 
dertnatitis. 
Leukocyte enzyme activity was measured by ra-
dioenzytne assay, whereas prostaglandin E2 and in-
terleukins 10 (IL-10) and 4 (IL-4) were tneasured in 
24-h culture supernatants of mononuclear leukocytes 
by itntnunoassays. The effect of a topical phosphodi-
esterase inhibitor on atopic dermatitis lesional skin 
was assessed by double-blind, paired cotnparisons of 
active drug and placebo ointments applied to sym-
tnetrically involved sites over a 28-d period. 
C yclic nucleotide Ph. osphodiesterases comprise a [.'1111-ily of isoenzymes that hydrolyze the 3' ,5 ' - cyclic nucleotides to 5 ' -nucleo tide m onophosphates (Beavo, 1988). W e have been particularly inter-ested in cAMP phosphodiesterase (PDE), because o f 
the increased cAMP hydro lytic activity in le ukocytes from patien ts 
with atopic dermatitis (AD) , asthma , and allergic rhinitis (Grewe e( 
ai, 1982) . T hese diseases represent a symptom compl ex character-
ized by immunologic hyper-reactivity and by inappropriate inflam-
m atory cell infLltra tion into skin and respiratory ti ssues . T he 
abnormal PDE activity correlates with le ukocyte fun ctional de fects 
including basophi l histamine hyper-releasibility (Butler e( ai, 1983 ) 
and increased B-lymphocyte JgE production (C oo per et ai, 198 5) , 
bo th o f which are normalized by ill vilro incubatio n with th e PDE 
inhibito r (PDE-i), R o 20-1 724. 
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Using in vitl'O assays, we detnonstrated the ability of 
selective high-potency phosphodiesterase inhibitors 
to reduce prostaglandin E 2 , IL-IO, and IL-4 produc-
tion in atopic tnononuclear leukocyte cultures. We 
selected the Type 4 phosphodiesterase inhibitor, 
CP80,633, based on its inhibitory potency, for clinical 
testing by topical, bilateral paired cotnparisons in 20 
patients with atopic dertnatitis and detnonstrated 
significant reductions of all inflatnmatory parame-
ters. 
Phosphodiesterase inhibitors tnodulate several 
pathways contributing to the exaggerated itntnune 
and inflatntnatory responses, which characterize 
atopic dertnatitis. This i" "ivo detnonstration of anti-
inflamtnatory efficacy tnay provide a useful alterna-
tive to the over-reliance on corticosteroid therapy in 
atopic disease . K eJ' lVol'ds: PDEIIL-4IIL-10ImolloCJItes. 
] I"vest D eYlllatol 107:51-56, 1996 
Phosphodies terases have in recen t years been classified in to seven 
famili es (Types I-V II or , by geno m e terminology, PDEl -7) accord-
ing to a number of characteristi cs including sensit ivity to inhibi tors 
(Beavo, 1990) . In previo us studies, we fo und evidence that the 
m o re active PDE4 in ato pic le ukocytes h ad increased sensitivity to 
inhibitio n by R o 20-1 724 and o ther agen ts (G iu stin a et ai, 1984; 
C han and H anifin , 1993) , com pared to PDE in normal leukocytes . 
W e ha ve u tilized this technique to assay th e po tency of PDE4 
inhibito rs, comparing e ffects o n PDE activity in ato pic and no rmal 
m o nonucl ear le ukocytcs (MNL) (C han and Hani fi n , 1993) . In this 
study, w e condu cted an ill lI ilro survey of several compo unds shown 
to be potent PDE4 inhibitors. Am ong these, we fo und chat two 
enantiom e rs, C P80,633 (Cohan el ai, 1995) and C P! 02,995, and the 
racem ate, C P76,593 , had the highest po tency in comparison to 
other agents. Consistent w ith pas t studi es (Giu stina et ai, 1984; 
C han and H anifin , 1993) , th ese compounds showed a greater 
re lative specificity for the atopic compared to the normal PDE 
isoenzym e. T hese techniques appear to provide a re levant ;'1 1i lro 
system fo r predicting the therape utic effi cacy of each new PDE-i in 
the m anagem ent o f AD, as thma, and othe r inflam matory diseases. 
Focusing o n the high er potency inhibi to rs of POE, we assayed the 
effectiveness of new compo und s o n eicosano id and CytokillC pro-
duction ill )Jilro . W e thcn carricd o u t a do uble-blin d , vehicle-
controlled , paircd-compariso n study to assess the safety and efficacy 
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of one of the new compounds whe n applied topicaUy for treatment 
of AD . Our studies d emonstrate that these PDE inhibitors modulate 
multiple immune and inflammatory pathways and signifi can tly 
r cducc signs and symptohlS of atopic inflammation. 
MATERI ALS AND METHODS 
RPMI-1640 m edium, Gey's balanccd sa lt solution, fetal bovinc serum 
(FBS), neuraminidase, Hanks' balanccd salt solutio n , Hanks' calcium/ 
magnes ium-free balanced salt so lution: Gibeo (Grand Island, NY). 5'-
Nucleotidase, cAMP, imidazole, 'lI1d snake vcnom (5' -nucleotidase): Sigma 
C hemical Co., St. Louis. MO . Hypaquc-Ficoll: Phannacia, Piscataway, NJ. 
I' H]cA MP (36 C i/mmol): Ncw England Nuclear, Boston. MA. Ion ex-
changc resin AG1 X2 (200-400 m esh) : Bio- Rad, Riclunond , CA. " R cady-
Solv" scintillation Auid : Bcckman, San J ose. CA. Anti-CD3 (OKT3): O rtho 
Diagnostics, Rahway, NJ . R.o 20-1724 was a gift from Holtillann LaRoche, 
Nutley, NJ . CP76,593 and its resolved cnantio mcrs. C P80,633 (Cohan ef ai, 
1995) and C P102.995, werc receivcd from Ccntral R esearch Divisio n , 
Pfizer Inc., Groton, CT. 
Subjects All subjccts gave informcd conscnt approved by the institutional 
Hunian Rcsearch Conimittee, Fo r Icukocyte studies, venous blood was 
drawn at 8:00 a.m., and immediate ly mixed with heparin (10 units/m l) for 
furthcr processing. Normal, hea lthy subjects had no pe rsona l history of 
asthma. allef!~i c rhinjtis. or AD. Patients with active AD were chosen 
acco rding to well-defined criteri a (Hanifin and R.ajka, 1980) and b lood 
d onors had moderate to severe disease. Blood dono rs' ages ranged from 25 
td 52 years (9 males and 11 fcmales) for normal subjects and 20 to 50 years 
for AD subjects (10 malcs and 8 fcmales) . Individual experimcnts wcre no t 
prccisely age- and gender-matched, because leukocytes were used in 
vario us assays on an y given day. Subjects for the clinical trial had lesions not 
exceeding 20% of tota l body surface area. No donors had received 
antihistalnine or topica l corticosteroid therapy for at least 96 h prior to 
stud y, and none had used systemic adrenergic, PDE inhibitors, Or corti co-
stero id m edica tio ns for at least 1 mo. No caffe ine or other methylxanthine-
containing beveragcs were consumed within 14 h prior to leukocyte studies. 
Cell Preparations Blood was separatcd by Hypaque-Fico ll gradient 
centrifugatio n at 400 X g for 30 min, and MNL were harvested frolll the 
interphasc of plasma and separation fluid (Chan and H anifin, 1993). The 
cell s were washed three times w ith sa line and spun at 400, 300 , and 250 X 
g sequentiall y to eliminatc platelet contamination. MNL were harvestcd and 
coun ted using a Coul ter COunter. Differential-Iymphocytc and -monocyte 
qu iJl1titations utilized Giemsa and acid naphthyl ace tate esterase stains and 
latcx bead phagocytic inges tion . T hese quantitations were monitored in all 
preparatio ns and showed no differences bctween AD and normal subjects in 
terms of perccntages of monocytcs and lymphocytes. MNL were either 
freeze-thawcd three times in an ace to ne-dry ice bath, and the homogcnates 
were stored at - 80°C un ti l assayed fo r homogcnatePDE activity, or 
culturcd as described be low. To o btain mo nocytes , MNL at 4 X 10" 
cclls/ml were allowcd to ad hcre in a 16- X 100-mm petri dish for at least 
2 h at 37°C in RPMI-1 640 + 10'Y., FBS. The nonadherent cc ll s were 
decanted and washed three times with warm Gey's balanced sa le solution . 
The adherent monocytes wcre recovered by sc raping w ith a steri le rubber 
policclilan. The MNL compos itions , de termined by Stat Sta in (Vo lu-Sol; 
Logos Scicntifi c, H enderson , NV) , contained 10-40'Yo m o nocytes, 60-70% 
lymphocytes , S 2"I., polymorphonuclear leukocytes, and S 5% platelets. T he 
Ilonadherent ce ll s werc typica ll y 2: 95% C D3 + Iymphocytcs. Cell viabi ljty, 
monj to red by trypan b lue exclusio n test, was always > 98%. Monocyte 
purity in tli e adherent cell preparatio ns, confirmed by acid naphthyl acetate 
esterase and Factor XI II illlnlunope roxidasc sta ining. was ==: 95'X,. 
For PGE2 production , monocytes (2 X 10"/ml) were incubated in 
R.PM I- 1640110% FBS. For IL-4 production, MNL (2 X 106/m l) were 
incubated in RPM 1- 1640/1 0% FDS with 10 ng/ml anti-C D3 (C han et nl, 
1993) . Afte r 24 h , supernatants were harvested by pe ll eting ce lls at 700 X 
g. 
PDE Inhibition/Assay Homogenized leukocyte preparations werc kept 
at 4°C . and various PDE inhibito rs wcre immediate ly addcd . All inhibitors 
were di ssolved in 50% e thano l at a concentration of 1 0- 2 M , then further 
diluted in Gey's balanced salt so lution to appropriate concentr;,tions. For the 
dcte rmination of IC sn, 1 O- H to J 0 - " M final concentrations of inhjbitors o r 
contro l buffer wcre used . The mixtures were thcn incubated at 37"<:: for 60 
min . PD E activiti es were determined in the presence of the inhibitors o r in 
contro l buffers in all experiments. Ro 20-1724 was used as a re ferencc 
compo und fo r comparison of inhibi to r e fFe cts in all studies. Maximum 
inhibitio n fo r each compo und was determined by curve-fittin g w ith a 
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computer program , and the concentration g iving 50'% of maximum inhibi-
tion was recorded as IC sll ' 
PDE was assayed using a modified method of T hompson ef al (1979) . The 
incubation mixture (0.4 ml) containcd 1 f.LM tAMP, 200,000 cpm of 
1"H]cAMP, and 0.2 ml o f sample (107 cells/ml) o r standard PDE in 40 mM 
Tris-Cl buffer (pH 8.0) containing 3.75 111M !3-mercaptoethano] and 15 mM 
MgCI2 • After incubation at 30°C for 10 min, the reaction was tcrminated by 
snap-freezing in ethanol-dry ice ["nh and the mixture was thcn boiled for 1 
min. Purificd 5' -nucleotidase w~' s added to the mixtu res, whjch were then 
further in cubate d for 10 111ln at 30°C and then transferred to Pa steur pipe tte 
columns containiilg ion exchangc resin AGI X2 to rClllove the remaining 
nucleotidcs and nucleosides. T he radioactivity in the e luates was quantitated 
in scintiUa tion Auid. Enzyme activity was expresscd as picom o les of cAMP 
hydrolyzed per f.Lg o f protein. Protein concentration was determined by an 
assay using Bio-Rad protein dye . A standard PDE fi'om bovine heart was 
L(sed to monitor consistcncy and recovery in each assay (C han and Hanitin , 
1993). 
InllTIunoassays Prostaglandin E 2 (PGE2) was assayed by radioimmuno-
assay as previously described (Chan et ai, 1993) , using cul ture supernatants 
containing 0.05 mM indomethacin as blank. POE2 antisera were produced 
in rabbits accordilig to the mcthod of JafFe and Beh.rman (1974). PGE2 was 
conjugated to porcine thyroglobulin by the mixed anhydride method before 
immunization of the rabbits. At a di lution of 1 :6000, thc PGE2 anti se rum 
had a sell sitivity of 10 pg/0.1 ml of sample and the fo llowi ng ccoss-
rcactivities at B/ Du 50% were: PGD2 , 0.8%; PGF2 " . 1%; PGF ,,, . 0 ,3%; 
PGE " 9.3%; 6-keto-PGF, a' 2 .2%; and 6-keto-PGE2 , 2%, as prev io llsly 
reported (Ge issler ef ai, 1989). 
Quantitative determinatio n o f human IL-4 was perfo rmed using enzYll1c-
linked il1ll11un osorbent assay (ELISA) kits (R & D System s, Minneapoli s, 
MN) with modifIcation to increase scnsiti vity (Li cf ai, 1993). The practical 
sens itivi ty of the assay was 5 pg/ml. In order to ,ileasurc below 5 pg/ml. the 
ELISA procedure was modiflcd , according to manuf.1cturer 's instructions, 
by extending the color development time at low concentrations fro m 15 to 
45 min to gcnerate a linear sca le be tween 0 and 5 pg/ m l. A human I L-I 0 
ELISA kit was also used to determ ine IL-1 0 concentrations. T he lower limit 
of detection was 7 .8 pg/m l for undiluted m o nocyte culturc supe rnatants. 
PDE inhibitors did not interfere with the IL-IO standard curves. 
Topical Therapy Twenty patients with AD (12 males and 8 femal es) 
aged 18 to 50 years were enro lled in the study to dctermine e fri cacy of 
topical C P80,633 ointmen t for treatment of skin inAal11matio n. Exclusions 
included fema les with childbearin g potential , pregnant or nursin g women, 
and patients who requi red any m edication that might interact with or 
obscure treatmcnt cffccts including the use of oral theophyll ine derivatives, 
ora l, parente ral. or to pically applicd corticosteroids, and H1 or H 2 anti lu s-
tamines . Patients had to DC in good health with normal laborato ry param-
eters and clcctrocardiogral11 s. 
The study design was a right/ left paired-comparison study to compare the 
efricacy of topica ll y applied CP80,633 (0.5%) ointmcn t twice dai ly fo r 28 d 
with its petro latum vehicle o n 200-cm2 lesional areas. Active drug and 
vehiclc were ass igned by sidc in a randomized, double-b lind fas luo n. 
Patients were selected for the presence of symmctricall y in vo lvcd anatom-
ica l sites 011 the right and left sides excluding the hands, feet, and face. 
Grading each of thrce inflammatory parameters I.(i) erythema; (ii) indura-
tion / papulation; (iii) excoriation] uti li zed a scale from 0 to 3 (1 = mild. 2 = 
moderate, 3 = sevcre, with half steps) and base line scores were required to 
be at least 6 of thc poss ible 9 for the total c1jn ical sco re. The subjective itch 
scorc was likewisc graded on a scale of 0-3 . After physical examination , 
blood chemistries [alkaLinc phosphatase, alaninc and aspartate aminotr'llIs-
fcrase (ALT and AST) , Na +. K+, Cl - , glucose . uri c acid, b lood urea 
nitrogen , creatinine, and tota l bilirubin], urinalysis and hematology (com-
plete blood count w ith differential) we re obtaincd fi'ol11 vcnous blood. 
Study drug was app lied twice daily for 28 d of treatnient. Overa ll efficacy 
assessm ents werc made at days 3 , 7, 14, 21, and 28 to grade improvement 
or worselung of inAammatory signs, determined by comparing to baseline 
scores the spccific parameters and the total clinica l scorc. Repeat I"boratory 
cva luations were performcd at days 7, 14, and 28 or at the time of ca rly 
di scontinuatiOll . Electrocardiogram was repeated at the end of study. 
Statistical AlHllysis Por ill "ilm studies comparing ICsll v" lucs of PDE 
and IL-4 production in cu ltures , Student's t test was used, w hereas 
Mann-Whitney nonparamctric analysis was used in comparing e fr'c cts of 
PDE inlubitors on PGE2 and IL-10 prod·uction. For c1jnical studies, individ-
ua l parame tcr scores and thc sum of scorcs w c re compared for active and 
placebo-treated sites . The score at each time point was subtracted from the 
base line score and this change ,.vas analyzed using two-sided t tests, 
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Table I. Comparison of 50% Inhibition Concentrations 
(ICso) Against Phosphodiesterase Activity in 
Homogenates of Mononuclear Leukocytes from Patients 
with Atopic Dermatitis (AD) and from Normal Subjects" 
Phosphodies terasc 
Inhibi to rs 
Pentoxyfyllinc 
R olipram 
T heophylline 
R o 20-1 724 
C P76 ,593 
C PSO,633 
C PI 02,995 
IC, " (J..LM . mean :<: SEM) 
AD (n)" 
1.76 :<: 0.26 (4) 
0.86 :<: 0.22 (7) 
27.11 :<: 12.43 (7) 
0.1 7 :<: 0.08 (8) 
0.32:<: 0.1 2 ('II) 
0.015 :<: 0.003 (10) 
0.88 :<: 0.007 (8) 
Normal (n) 
3.58 :<: 1.22 (3) 
1.13 ± 1.86 (7) 
87.92 :<: 19.68 (9) 
2.9 ± 0.55 (8) 
4.43 ± 1.60 (5) 
NO 
NO 
Values" 
0.045 
0.037 
0.027 
0.0076 
0.00 176 
(/ I: jcoll - H ypaq uc g radient-separa ted pcrip ltcral blood m Ollo llucicar leu kocytes were 
ho m ogen ized and in cubMcd w ith tinal concentratio ns of each inhibitor ranged from 
10- 8 to I a- 'IM to detcnnnc their Ie , ,, for the inhibi tion of POE activity. 
I, (n) = 110. o r donors: N D = not dO lle. 
r p va lues were determined by Studeo t's t tcst comparing IC Sil be tween no rmal and 
AD. 
employing a lcvcl of significance (p < 0.05) to test the alternative 
hypothesis that the mean paired di ffe rence is not equal to zero. 
RES ULTS 
Greater Type 4 Inhibition of Atopic PDE O ur first objective 
was to compare poten c ies o f n ew er Type 4 inhibito rs with presently 
available agents o n POE ac tivi ty in MNL homogenates . W e initially 
d e te rmin ed m ea n IC su values of POE inhibitio n in MNL h o m oge-
na tes b y the racemic mixtures C P76 ,5 93, for both normal and AD 
g roups (Table I) , and compared these m ean rc s" va lues fi'o l11 AD 
and normal g ro ups with those of p entoxyfylline , rolipram, theoph-
ylline, and R o 20- 1724. R esults sho w ed that C P7 6,593, which was 
sli ghtl y less po tent than R o 20-1724, was more ac tive against the 
A D isozym e th an the o the r inhibi tors. Each o f th ese compo unds 
had less p otency against the n o rm al isozym e, consistent w ith our 
p revio us findin gs (G iustina et ai , 1984; C h an and H anifin , 1993 ) . 
W e th en compared pure enantio m e rs ( + ) C P80 ,633 and ( - ) 
C P1 02,995, with (± ) C P76 ,593 and fo und tha t C P80 ,633 was 21-
and 59-fo ld m o re inhibitory than e ith e r C P76,593 (p < 0.0 1) o r 
C PI02,995 (p = 0 .008), respec tive ly, against the PO E in MNL 
fro m patie nts with AD (Table I) . C P80 ,633 was also significantly 
m o re ac tive th an R o 20-1724 (p < 0. 001) . Beca use the focus of o ur 
studies w as AD inflammation, pure en antio m ers w e re n o t tes ted on 
normal cells. 
PDE Inhibitors Reduce Atopic Monocyte PGEz and IL- 10 
Production W e recently reported in creased spontan eou s PGE2 
(C han et ai, 1993 ) and lL-1 0 (O hmen el ai, '1995) pro ductio n by 
c ultured m on ocytes fro m patients with AD . W e fo und that th ese 
inc re ases correspo nded w ith e levated POE ac tiv ity ,md h yp o thesize 
tha t this results in inad equa te cAMP m o du lati on o f m o n ocyte 
fun c ti on (C han cl ai, 1993 ) . To evalua te th e efFect of POE 
inhibitors, PGE2 levels w e re m easured by radio immuno assay in 
24-h cu lture supern atan ts fro m m o nocytes trea ted with C P80, 633 
(0 .1 J.LM) o r R o 20-1 724 (1 J.LM) , comparin g AD and normal 
preparatio n s. T h e con centra tions of the inhibitors u sed w ere chosen 
fo r the ir respecti ve m aximal e ffects, as de te rmined by dose-re-
sp o nse curves. Untreated contro l cul tures confirmed previo u s 
findin gs o f markedl y e levated m ean PGEz leve ls in AD preparations 
(562 ± 107 /lcr SIIS 89 ± 27 fo r n o rma ls, m ean ± SEM p = 0 .0036; 
Fig 1) . B o th C P80,633 and R o 20-1724 cau sed significant reduc-
tion s in PGE2 supern atant levels in A 0 compared to the untreated 
contro l cul ture (n = 4 - 8) . R o 20-1 724 did n o t a.ff'ect PGE 2 
p rodu ctio n in n o rm al ce lJ cultures. T his was consistent with the 
re duced enzym e inhibition in n o rmal cell s (Table I) and with 
previous fmdin gs o f increased inhibito r sensiti v ity o f atopic PDE 
(G iustina cl ai, 1984; C han and Hanifin, 1993 ). T he PGE2 changes 
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Figure 1. Prostaglandin E2 levels in lTlonocyte culture superna-
tants. Prostaglandin E2 (PGE2) levels (pg/ ml , mean ± SEM) in unstimu-
lated culture supernatants from atopic dermatitis (AD) and normal mono-
cytes cultured for 24 h with media alone (0) , R o 20-1724 (1 J..LM. ~). or 
C P80,633 (0. 1 J..LM, .; not done in normals) . ' p = 0.004 . t p < 0.001. 
U1 R o 20-1724 and C P80,633-trea te d AD cell cultures were 
significant (p < 0 .001 and < 0 .001, r espectively) by M ann-
Whitney. 
W e also compared R o 20-1 724 and C P80 ,633 inhibition of AD 
m o nocyte IL-10 produ ction in a d ose-resp Oli se experim en t (Fig 2) . 
T he con centration o f C P80 ,633 required fo r 50% inhibitio n of 
IL-l 0 (I C so) w as 2.2 nM , indicating a lOOO-fold g reater po tency 
than R o 20-1724 (IC so = 2.5 J.LM) in reducing pro duction of t1us 
cytokine (p < 0 .00 1, b y M ann-W hitney test) . Initial experiments 
using th e usual 10 - 7 M C P 80 ,633 con centra tion sh owed 94% an d 
100'!!o inhibiti on o f spo ntan eous IL-10 produc tion in n ormal (n = 2) 
and AD (n = 4) m o nocyte cultures, respective ly . M ean spontane-
o us IL-IO pro duc tion in these studies by n orm al monocytes was 578 
± 11 8 p g/ml (n = 2) and 1962 ± 276 pg/ml (n = 5) by AD 
m o n ocytes. 
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Figure 2. Dose effec t of PDE inhibitors on lTlonocyte IL-tO pro-
duction. Dose-related inhibition of spontaneous atopic monocyte IL-10 
production by R o 20-1 724 (0 ) and C P80.633 (.). Spontaneous IL-I 0 
production fo r this donor was 2330 pg/m1. 
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Table II . PDE Inhibitor Effect s on IL-4 Production" 
AD (n) p va luc/' Normal (n) p value/' 
Contro l 42.6 :!: 6.7 (8) 17.6 :!: 1.9 (6) 
+ Ro 20-1724 5.2 :!: 2.1 (6) 0.003 14.2 :!: 1.6 (6) NS' 
+ CP80,633 2.4 :!: 2.5 (3) 0.036 2'1.9 :!: 4.6 (3) NS 
,I Mononuclear le ukocytes were cul tured fo r 2 ~1 II w ith anti-CD3 (10 Ilg/ml) ± Ro 
20-1724 ( I /-tM) or C P80.G33 (0 .1 /-tM). Supernatant IL-4 levels we re measured by 
ELI SA and ex pressed ;15 pg/ m l mean :t SEM. 
I! P va lue co m paring; inh ibitor effect to cOll trols. 
r NS = nor signi fic.mt. 
R e duce d IL -4 P r oduction We previo usly noted an inverse 
re lationshi p between eleva ted POE activ ity and redu ced in terfer-
o n- ')I (IFN- ')I) levels in atopic MNL (Chan el ai , 1993) and reasoned 
that in creased IL- 4 pro du ction migh t li kewise rela te to abnormal 
POE activ ity. We assessed th e e ffect of P DE inhjbi tors on IL-4 
productio n determin ed by ELISA from supernatants o f anti-C D 3-
stim ulated AD and no rmal 24-b MNL cultures , with and with o ut 
PDE inhibi tors. As can be seen in Table II , both R o 20-1724 (1 
f.LM ) and CP80,633 (0 .1 f.LM) ca used 8- and l 8-fo ld redu ctions, 
respectively, ill AD supernatant concentratio ns. T hese inlubi to rs 
had no effect o n no rmal lL-4 supe rn atan t levels. 
T o p ical CP80,633 a s an Anti-Inflammatory Agent Based on 
its dem o nstrated POE inhibitory po tency, C P80,633 was selected 
for cl inical testin g . Twenty pa tien ts with AO we re enroll ed in a 
clinical trial to assess the efficacy and sa fety of CP80,633. Symmet-
rica.l , m o derate ly involved areas of up to 200 cm 2 on each of the 
righ t and left sides were selected fo r assessm en t o f ac tive IIerSIIS 
placebo therapy. T he base line mean to tal scores at bilate ral sites 
were comparable (5.20 ::!:: 0.22 IIcrS IIS 5 .33 ::!:: 0 .1 9, P = 0.2 7). 
Effi cacy evalu ations were recorded at days 3, 7, 14. 21, and 28 
d uring the rapy . Infl ammatio n was qu anti ta ted b y the sa me o bserver 
grading erythema , induration / papulatio n , and excoriation o n a 
sca le fro m 0 to 3 (none, mild , mo derate, o r severe). Baselin e scores 
compared w ith those at day 28 showed signi fica n t improvem ent o n 
sites rece iving CP80,633 w ith mean reductio ns in eryth em a (p = 
0.004), induration (p < 0.001), and excori ati ons (p = 0 .046) , the 
latter servi ng as an obj ective indicator of pru ritu s. Patients were also 
asked to estim ate the level of itching at each visit, and the ir 
subj ective responses likewise show ed signifi can t improvem ent o n 
active compared to placebo- treated sites (p = 0 .002) . T he response 
to active drug was consistent amo ng the subjects, w ith an impro ve-
m en t in tota l clini cal score observed in 16 of 20 CP80,633-treated 
sites (F ig 3) , graded at th e last assessme nt, compared to o nly three 
of20 placebo-treated sites (mean ::!:: SD 1 .40 ::!:: 1.76 and - 0.65 ::!:: 
1.48, respectively; p < 0.001) . 
Figu re 4 shows the m ean change &om base line of the to tal 
cl injca l scores (erythe m a + induratio n + excoriati on) of ac ti ve and 
placebo-treated sites over the course of the study. Mean baseline 
scores were sim ilar fo r vehicle and C P80,633- treated sites. Signi f-
icantly reduced in flam m ation was ev iden t as earl y as d ay 3 and 
con tinued throughout the therapy phase fo r actively trea ted sites, 
w hich demonstrated signifi cantly grea te r improvem ent than pla-
cebo sites at each time point. Beca use we had previo usly de tected 
ill II il ro evidence of tach yphylaxis am o ng as thm atic patients trea ted 
w ith theoph ylline long- te rm (Giustina e( ai , 1984) we were inter-
ested in w hethe r tlus mi gh t occur wi th topical CP80 ,633 therapy; 
however, improveme nt continued thro ugho ut the 4-wk course o f 
treatm en t with ac ti ve drug . 
Adverse events indistinguishable £1'om m ani festatio ns of AD 
(itching, b urnin g, fo lliculitis) we re noted as sin gle events o n nine 
placebo- and nine vehicle- trea ted sites, and 16 of these 18 o bser-
vatio ns were b il atera l. In two ins tan ces, fo lliculiti s was no ted on the 
active d ru g-treated site and in two other patients, bil ateral fo llicu-
litis was noted. T hese events are typica l o f AD (H anifin and R ajka, 
1980) and the occu rrence o f folli culiti s in 5.3'Vu of acti ve site 
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Figure 3. Clinical effect of topical PDE inhibitor, CP80,633. Clin-
ical effect (change in mean total score of cunical parameters) of topical 
phosphodiesterase inhibi to r, CP80,633, on bilateral atopic dermatiti s le-
sions. Each poin t represents the di fference between total clinical score at 
baseline and the score at the last observed assessment. 
o bservatio ns w as not signifi cantly grea ter than the 2.6% frequency 
on ve hicle-treated sites . T he re w ere no drop-o uts for ad verse 
events and no clinically relevant laborato ry or e lectrocardiogram 
changes. Eight patients di sconti nued be fo re the end o f the treat-
m en t period , al\ due to flarin g o f de rma titis o n untreated areas (no 
o th er th erapy was all o w ed durin g th e course of the trial) . In three 
of the eight patients, dermatiti s becam e in to lerable o n one side , the 
pl acebo-trea ted side; in the othe r fi ve patients, the study was 
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Figure 4. Titne-course of change ill clinical scores for active " US US 
placebo-treated atopic dermatitis lesions_ Longitudinal pattern of 
clinical response reflected by mean change (:!: SEM) from baseune total 
cl inica l scores of topical CP80,633 (_) "ersliS plilcebo-treated atopic derma-
titis (0 ) sites. Significant improvement was evident at each time poin t (p 
values indicated) ; n = number of subjccts evaluated at each time poin t 
during therapy (days 3-28). 
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discontinued because of genera lized worsening of the untreated 
dermatitis. 
DISCUSSION 
Atopic dermatitis, a chronic inflammatory skin disease, causes 
severe pruritus leading to excoriation and secondary infection. 
Economicall y, AO creates a considerable health care burden (Lapi-
dus et ai, 1993), accoun ting for 1% of pediatric ou tpatient visits 
(Sampson, 1990) and, beca use of li fe long cutaneous hyp erirritabiJ-
ity, over 80% of occupational skin disease (Shmunes and Keil , 1983; 
Nassif et ai, 1994) . T herapeutic options for AO, as fo r all ergic 
respiratory disease, are limited and inadequate . Glucocorticoste-
roids are used aJmost excl usively, but toxic effects are eviden t in 
many patients . For some very severe cases, photochem otherapy, 
cyclosporin A, or IFN-y are used, but these are high-risk, expen-
sive , and generall y unsatisfactory modalities. Safe, effective anti-
inflammatory agents for treatment of AD are perhaps the greatest 
need and challenge in dermato logic disease. 
AJtered cyclic nucleotide metabo li sm in atopic disease was 
predicted previo usly by Szentivan yi (l968). T his led to a series of 
studies that demonstrated blunting of cA MP responses in leuko-
cytes of patients with AD. We showed that this defect was caused 
by high cAMP hyd ro lysis by POE in atopic leukocytes (Grewe el ai, 
1982; B utler cl ai, 1983). T he increased POE activity was present 
even in cord blood cells of newborns from atopic parents (Heskel 
et ai, 1984), indicating an intrinsic, possibly genetica lly controll ed 
abnormali ty. We demonstrated that the increased POE correlated 
with histamine hyper-releasibili ty and w ith e levated spontaneous 
IgE production in cultl1L'ed AD leukocytes, and we showed that 
POE inhibitors could normalize those functions (Butl er et ai, 1983; 
Cooper cl ai, 1985). 
Other studies demonstrated that the atopi c isoenzymes were 
distinctly more sensitive to each POE-i (Giustina ct ai, 1984; C han 
and Hanifin , 1993), suggesting th at these agen ts have a therapeutic 
advantage in AD. Our studies have focused particularly on blood 
monocytes w hich have a major proportion of abnormal POE 
activity. We recently presented evidence that AD monocytes also 
have a considerable immune mod ul ating effect on T cells. IFN-y 
production, w hich is reduced in MNL cultures, became norm al o r 
e levated in puri fied T-cell cultures, indicating a monocyte inhibi-
tory effect on Type 1 T helper cells (Thl) (Chan el ai, 1993). T his 
led to the demonstration of in creased spontaneous production of 
PGE2 (Chan cl ai , 1993) and IL-1 0 (Ohm en eI ai , 1995), both 
known suppressors of IFN-y production by T Il1 cells. 
T hese studies strongly suggest that increased POE activ ity re-
duces in tracellular cAMP levels that, in turn , allow greater basal 
monocyte secretion of T -cell modu la tors. Because of the associa-
tion of increased POE activity with the elevated PGE2 and lL-10 
production in AD monocytes, we reasoned that each POE-i might 
correct these abnorm ali ties. Comparisons in enzyme inhibition 
assays (Ta ble I) showed that a new agent, CP80,633, was 10-fold 
more potent than the standard Type 4 inhibi tor, Ro 20-1724. W e 
fou nd that CP80,633 had a greater inhibitory effect on PGE2 and 
IL-10 production by AO m onocytes and on IL-4 prod uction in 
cultures of MNL. W e cannot clearly state w he tlle r the IL-4 effect 
was indirect, by inhibiting m onocyte m odula ting f.Kto rs, o r oc-
curred directl y on Type 2 T he lper (Th2) ce ll s. It co uld also be a 
combined efFect, because we have o bserved POE inhibition in 
lymphocytes, tho ugh this action occurred w ith a specific Type III 
inhibitor, nitraquazone (Chan and Hanifin, 1993), and CP80,633 is 
not an inhibi tor of Type III POE (Cohan el ai, 1995). 
It seems reasonable to consider that abnormal POE isoenzymes 
underli e many of the immune and inflammatory abnormalities of 
atopic disease . We have demonstrated that inhibition of POE 
influences a number of cellular and m ediator pathways including 
monocyte PGE2 and IL-IO syn thesis, and IL-4 over-production. 
Because of CP80,633's effects in enzyme and cytokine inhibition 
and other predi ctive assays (Cohan el ai, 1995), as well as the 
distinctly higher sensitivity of AD enzyme to POE inhibi tors, we 
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tested the drug in clinical studies, comparing active 0.5% CP80,633 
Witil placebo o intment vehicle applied to symmetrical right and left 
lesions in 20 patients with AO . R espon ses were prompt, showing 
statistically significant improvement w ithin 3 d and maintaining 
throughout the 28- d tria l. T he drug reduced inflammation in 80% 
(16 of 20) treated sites, as compared to only 3 of 20 placebo sites. 
Importantly, no irritation or other adverse events were observed in 
a disease notoriously subject to irritancy. 
Topical treatmen t is the prefelTed m e tilod for most patients w ith 
AO and is an area of great need because of the common involve-
ment of face and eyelids, thin-skinned areas in w hich corticoste-
roids may ca use atrophy. Systemic use of POE inhibitors has been 
limited by side effects, particularly the common nausea and vom-
iting resulting from use of high-dose theophylline, and a particula.r 
problem with newer, more potent agents (Torphy and Undem, 
1991); however, this high potency compound , CP80,633, clearly 
reduces atopic inflammation when applied topicaJly on the skin . To 
date, we have noted no evidence of emesis or other side effects with 
topical use, th ough considerable absorption might be expected if 
large areas of skin were treated. Our study suggests that drugs of 
this type may also have poten tia l for treating asthma via the inhaJant 
topical route. 
The clinical anti-inflammatory effectiveness by a potent Type 4 
POE-i applied to the skin confirms predictions from ill "ilro studies. 
This class of drugs, by increasing intracellular cAMP levels and 
reduciJlg cytokiJle and mediator release, modulates exaggerated 
atopic responses by multiple immune and inflammatory cells. Single 
pathway inhibi tors may be inadequate for controlling the m any 
facets of inA ammatory responses . It is hoped that this ill IIillO 
demonstration of efficacy will encourage development of useful 
alternatives to replace over-reliance on toxic corticosteroids in 
atopic disease. 
T il is lIIork II'as sllpp0I1ed bl' N aliolla/ [IIslilm"s 'if H ea/til Crnllts A 11 8615, 
AI34578, alld AI7758. 
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